Anis A. Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anis A. Khan has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Negro
Oncology R&D, AstraZeneca, Gaithersburg, Maryland
15 shared publications - Diansong Zhou
AstraZeneca Waltham Massachusetts USA
15 shared publications - Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center, New York, New York, USA
15 shared publications - John F. Kurland
Oncology R&D, AstraZeneca, Gaithersburg, Maryland
15 shared publications - Kun Wang
Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China
15 shared publications - KyoungSoo Lim
AstraZeneca 16 , Gaithersburg, Maryland
15 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Data for publication
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Data for publication
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S2. The effect of covariates, body weight, baseline albumin level, and combination therapy, on tremelimumab exposure metric Cmin1 (PK analysis population)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S2. The effect of covariates, body weight, baseline albumin level, and combination therapy, on tremelimumab exposure metric Cmin1 (PK analysis population)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S3. CFB of proliferating CD8+Ki67+ T cells vs predicted tremelimumab exposure (PD analysis population) in patients with lower and higher baseline CD8+Ki67+ T-cell counts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S3. CFB of proliferating CD8+Ki67+ T cells vs predicted tremelimumab exposure (PD analysis population) in patients with lower and higher baseline CD8+Ki67+ T-cell counts
- 9 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2672-2683
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
Aims: Cotadutide is a dual glucagon‐like peptide‐1/glucagon receptor agonist. The objective of the analysis was to develop a pharmacokinetic‐pharmacodynamic (PK/PD) model to describe the relationship between cotadutide exposure and response on urine albumin‐to‐creatinine ratio (UACR), urinary albumin (UALB), and body weight in participants with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) using data from a Phase2b study (NCT04515849). Methods: A total of 247 participants with CKD and T2DM were randomized and titrated to either 100, 300 or 600 μg cotadutide, 1 mg semaglutide or placebo. UACR was measured biweekly from either morning void (Weeks 14 and 26) or spot urine (other visits). The analysis was implemented using a longitudinal non‐linear mixed‐effect model. The potential impact of covariates on efficacy in participants was quantified. Results: PK/PD models were developed, and a significant relationship was identified between cotadutide exposure and PD biomarkers of UACR, UALB and body weight. The models described the data adequately; greater changes in PD responses were observed with higher cotadutide doses. Baseline mean blood pressure and baseline UALB were found to affect the reductions in UACR and UALB, respectively. Model‐predicted relative change from placebo in UACR, UALB and body weight after 26 weeks of 600 μg cotadutide treatment were −45.6% (−52.4%, −38.7%), −47.2% (−56.0%, −39.9%) and −5.3% (−7.6%, −4.1%), respectively. Conclusions: This modelling assessment was successfully applied for cotadutide to understand the relationship between cotadutide dosing regimen and the response in UACR, UALB and body weight. These models have general application in analysing and interpreting data from CKD/diabetic kidney disease (DKD) studies.
- 9 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2672-2683
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
Aims: Cotadutide is a dual glucagon‐like peptide‐1/glucagon receptor agonist. The objective of the analysis was to develop a pharmacokinetic‐pharmacodynamic (PK/PD) model to describe the relationship between cotadutide exposure and response on urine albumin‐to‐creatinine ratio (UACR), urinary albumin (UALB), and body weight in participants with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) using data from a Phase2b study (NCT04515849). Methods: A total of 247 participants with CKD and T2DM were randomized and titrated to either 100, 300 or 600 μg cotadutide, 1 mg semaglutide or placebo. UACR was measured biweekly from either morning void (Weeks 14 and 26) or spot urine (other visits). The analysis was implemented using a longitudinal non‐linear mixed‐effect model. The potential impact of covariates on efficacy in participants was quantified. Results: PK/PD models were developed, and a significant relationship was identified between cotadutide exposure and PD biomarkers of UACR, UALB and body weight. The models described the data adequately; greater changes in PD responses were observed with higher cotadutide doses. Baseline mean blood pressure and baseline UALB were found to affect the reductions in UACR and UALB, respectively. Model‐predicted relative change from placebo in UACR, UALB and body weight after 26 weeks of 600 μg cotadutide treatment were −45.6% (−52.4%, −38.7%), −47.2% (−56.0%, −39.9%) and −5.3% (−7.6%, −4.1%), respectively. Conclusions: This modelling assessment was successfully applied for cotadutide to understand the relationship between cotadutide dosing regimen and the response in UACR, UALB and body weight. These models have general application in analysing and interpreting data from CKD/diabetic kidney disease (DKD) studies.
- Open Access
- 23 July 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (9) , 1582-1594
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach
Cotadutide is a dual glucagon‐like peptide‐1 (GLP‐1)/glucagon receptor agonist. Gastrointestinal adverse effects are known to be associated with GLP‐1 receptor agonism and can be mitigated through tolerance development via a gradual up‐titration. This analysis aimed to characterize the relationship between exposure and nausea incidence and to optimize titration schemes. The model was developed with pooled data from cotadutide‐administrated studies. Three different modeling approaches, proportional odds (PO), discrete‐time Markov, and two‐stage discrete‐time Markov models, were employed to characterize the exposure–nausea relationship. The severity of nausea was modeled as different states (non‐nausea, mild, and moderate/severe). The most appropriate model was selected to perform the covariate analysis, and the final covariate model was used to simulate the nausea event rates for various titration scenarios. The two Markov models demonstrated comparable performance and were better than the PO model. The covariate analysis was conducted with the standard Markov model for operational simplification and identified disease indications (NASH, obesity) and sex as covariates on Markov parameters. The simulations indicated that the biweekly titration with twofold dose escalation is superior to other titration schemes with a relatively low predicted nausea event rate at 600 μg (25%) and a shorter titration interval (8 weeks) to reach the therapeutic dose. The model can be utilized to optimize starting dose and titration schemes for other therapeutics in clinical trials to achieve an optimal risk–benefit balance and reach the therapeutic dose with minimal titration steps.
- 23 July 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (9) , 1582-1594
Open AccessExposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach
Cotadutide is a dual glucagon‐like peptide‐1 (GLP‐1)/glucagon receptor agonist. Gastrointestinal adverse effects are known to be associated with GLP‐1 receptor agonism and can be mitigated through tolerance development via a gradual up‐titration. This analysis aimed to characterize the relationship between exposure and nausea incidence and to optimize titration schemes. The model was developed with pooled data from cotadutide‐administrated studies. Three different modeling approaches, proportional odds (PO), discrete‐time Markov, and two‐stage discrete‐time Markov models, were employed to characterize the exposure–nausea relationship. The severity of nausea was modeled as different states (non‐nausea, mild, and moderate/severe). The most appropriate model was selected to perform the covariate analysis, and the final covariate model was used to simulate the nausea event rates for various titration scenarios. The two Markov models demonstrated comparable performance and were better than the PO model. The covariate analysis was conducted with the standard Markov model for operational simplification and identified disease indications (NASH, obesity) and sex as covariates on Markov parameters. The simulations indicated that the biweekly titration with twofold dose escalation is superior to other titration schemes with a relatively low predicted nausea event rate at 600 μg (25%) and a shorter titration interval (8 weeks) to reach the therapeutic dose. The model can be utilized to optimize starting dose and titration schemes for other therapeutics in clinical trials to achieve an optimal risk–benefit balance and reach the therapeutic dose with minimal titration steps.
- Top Cited PapersOpen Access
- 5 April 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (7) , 2443-2458
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Background: CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). Methods: Patients received oleclumab 5–40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W. Results: 192 patients were enrolled, 66 during escalation and 126 (42 CRC, 42 PDAC, 42 NSCLC) during expansion. No dose-limiting toxicities occurred during escalation. In the monotherapy and combination therapy escalation cohorts, treatment-related adverse events (TRAEs) occurred in 55 and 54%, respectively, the most common being fatigue (17 and 25%). In the CRC, PDAC, and NSCLC expansion cohorts, 60, 57, and 45% of patients had TRAEs, respectively; the most common were fatigue (15%), diarrhea (9%), and rash (7%). Free soluble CD73 and CD73 expression on peripheral T cells and tumor cells showed sustained decreases, accompanied by reduced CD73 enzymatic activity in tumor cells. Objective response rate during escalation was 0%. Response rates in the CRC, PDAC, and NSCLC expansion cohorts were 2.4% (1 complete response [CR]), 4.8% (1 CR, 1 partial response [PR]), and 9.5% (4 PRs), respectively; 6-month progression-free survival rates were 5.4, 13.2, and 16.0%. Conclusions: Oleclumab ± durvalumab had a manageable safety profile, with pharmacodynamic activity reflecting oleclumab’s mechanism of action. Evidence of antitumor activity was observed in tumor types that are generally immunotherapy resistant. Clinical trial registration: Clinicaltrials.gov, NCT02503774; date of registration, July 17, 2015.
- 5 April 2023
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (7) , 2443-2458
Top Cited PapersOpen AccessFirst-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Background: CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). Methods: Patients received oleclumab 5–40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg intravenously Q2W. Results: 192 patients were enrolled, 66 during escalation and 126 (42 CRC, 42 PDAC, 42 NSCLC) during expansion. No dose-limiting toxicities occurred during escalation. In the monotherapy and combination therapy escalation cohorts, treatment-related adverse events (TRAEs) occurred in 55 and 54%, respectively, the most common being fatigue (17 and 25%). In the CRC, PDAC, and NSCLC expansion cohorts, 60, 57, and 45% of patients had TRAEs, respectively; the most common were fatigue (15%), diarrhea (9%), and rash (7%). Free soluble CD73 and CD73 expression on peripheral T cells and tumor cells showed sustained decreases, accompanied by reduced CD73 enzymatic activity in tumor cells. Objective response rate during escalation was 0%. Response rates in the CRC, PDAC, and NSCLC expansion cohorts were 2.4% (1 complete response [CR]), 4.8% (1 CR, 1 partial response [PR]), and 9.5% (4 PRs), respectively; 6-month progression-free survival rates were 5.4, 13.2, and 16.0%. Conclusions: Oleclumab ± durvalumab had a manageable safety profile, with pharmacodynamic activity reflecting oleclumab’s mechanism of action. Evidence of antitumor activity was observed in tumor types that are generally immunotherapy resistant. Clinical trial registration: Clinicaltrials.gov, NCT02503774; date of registration, July 17, 2015.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S2. The effect of covariates, body weight, baseline albumin level, and combination therapy, on tremelimumab exposure metric Cmin1 (PK analysis population)
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S2. The effect of covariates, body weight, baseline albumin level, and combination therapy, on tremelimumab exposure metric Cmin1 (PK analysis population)
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets